SLC6A3 and attention deficit-hyperactivity disorder: If the DA and NE monomer components can be added as positive controls, and the changes in the dopamine transporter (DAT), NE transporter (NET) and other targets related to the dynamics of DA and NE can be investigated, it will help to further unravel the potential pharmacological mechanism of LMQXM in alleviating ADHD through upregulating DA and NE.